Patterns of presentation and outcomes in stage IV Hodgkin lymphoma: A report from the Children's Oncology Group (COG) AHOD1331 trial
A standard chemotherapy regimen improved survival in most advanced pediatric Hodgkin lymphoma patients, though bone marrow-involved cases need different strategies.
Analysis of 340 pediatric patients with stage IV classic Hodgkin lymphoma from COG AHOD1331 found the brentuximab vedotin-containing regimen improved 4-year progression-free survival across most stage IV subtypes but not in the bone marrow-only subgroup. This pattern-specific data identifies bone marrow involvement as a treatment modifier that may require novel strategies beyond Bv-AVEPC.
What the study was
- Study design
- randomized_controlled_trial_secondary_analysis
- Category
- hematologic_malignancies
- Maturity
- Potentially Practice-Changing
- Journal
- Br J Haematol
Why it surfaced
Important COG RCT subgroup analysis defining stage IV disease pattern as modifier of Bv-AVEPC benefit; identifies bone marrow-only involvement as a non-responder group needing novel approaches; clinically practice-changing for pediatric HL management.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.